Prospective Observational Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain (APPROPRIATE Study)
Phase of Trial: Phase IV
Latest Information Update: 14 Jan 2020
Price : $35 *
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms APPROPIATE; APPROPRIATE
- Sponsors Celgene Corporation
- 10 Jan 2020 Planned number of patients changed from 125 to 150.
- 10 Jan 2020 Status changed from active, no longer recruiting to recruiting.
- 11 Dec 2019 Planned End Date changed from 25 Jul 2020 to 25 Aug 2020.